Eli Lilly just turned up the heat in the obesity drug race. Its experimental combination therapy, EloraTZP — which pairs blockbuster ingredient tirzepatide with the novel drug eloralintide — outperformed Zepbound in a head-to-head mid-stage trial. Patients with type 2 diabetes on the highest EloraTZP dose lost an average of 23.3% of body weight over 48 weeks, compared to 14.8% for those on Zepbound's highest dose. The drug also cut blood sugar more effectively, reducing A1C by up to 2.9% versus 2.4% for tirzepatide alone.

The catch? Higher dropout rates. Between 10.8% and 27% of EloraTZP patients discontinued, compared to just 2.9% for tirzepatide alone, largely due to gastrointestinal side effects during dose escalation. Lilly says it plans to refine dosing schedules in upcoming late-stage trials, set to begin in Q4 2026.

By the Numbers:

• 23.3% average weight loss with EloraTZP (highest dose, 48 weeks) vs. 14.8% with Zepbound
• 2.9% A1C reduction with EloraTZP vs. 2.4% with tirzepatide alone
• 10.8%–27% discontinuation rate for EloraTZP vs. 2.9% for tirzepatide alone
• Global obesity drug market projected to hit $100B–$150B annually by decade's end

Why it matters: With Novo Nordisk's shares down more than 70% from their record highs and its own combo drug (CagriSema) already underperforming in trials, Lilly is positioning EloraTZP as a next-generation option for patients who need deeper weight loss or haven't responded adequately to existing therapies — a potentially significant clinical and commercial opportunity.